Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered

Documenti analoghi

• Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease
  di: Goláň, Lubor, et al.
  Pubblicazione: (2015)
• Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients
  di: Tsuboi, Kazuya, et al.
  Pubblicazione: (2017)
• 5PSQ-010 Efficacy and safety of agalsidase alfa in fabry disease
  di: Rosa, V González, et al.
  Pubblicazione: (2018)
• Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease
  di: Goker-Alpan, Ozlem, et al.
  Pubblicazione: (2015)
• An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy
  di: Goker-Alpan, Ozlem, et al.
  Pubblicazione: (2016)